Table 2.

Efficacy and safety outcomes of multiple procedure follow-up

	Total	BMI<30	BMI≥30	P values
Total n, PVI median (range)	2.0 (1–5)	2.0 (1–4)	2.0 (1–5)	0.505
Multiple procedure success
12 months FU no AAD, n (%)	119 (29%)	93 (31%)	26 (23%)	0.178
12 months with and without AAD, n (%)	221 (53%)	163 (54%)	58 (52%)	0.911
Long-term FU no AAD, n (%)	172 (42%)	139 (46%)	33 (30%)	0.005
Long-term FU with and without AAD, n (%)	268 (65%)	206 (68%)	62 (56%)	0.036
Major adverse events
Procedure-related death	0	0	0
Cardiac tamponade/perforation	9	5	4
Thromboembolic event	4	2	2
Air-embolic event	2	2	1
Total (multiple procedures)	16 (4%)	9 (3%)	7 (6%)	0.105
Minor adverse events
Femoral bleeding/aneurysm/AVF	14	9	5
Pericardial effusion no intervention	4	3	1
Phrenic nerve lesion	1	1	0
Pulmonary vein stenosis (asymptomatic)	1	1	0
Pericarditis	1	1	0
Total (multiple procedures)	21 (5%)	15 (5%)	6 (5%)	0.512
Major or minor adverse events (multiple procedures)	37 (9%)	24 (8%)	13 (12%)	0.158

AAD, antiarrhythmic drugs; AVF, arterial venous fistula; BMI, body mass index; FU, follow-up; PVI, pulmonary vein isolation.